• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    ACS medicinal chemistry letters

    ACS medicinal chemistry letters

    JournalISSN 1948-5875eISSN 1948-5875中科院 医学 3区

    年发文量

    研究主题

    论文(5198)

    排序
    1Novel Small Molecule Inhibitors of GSL-1 As Potential Agents for the Treatment of Metabolic Disorders
    Gerard Rosse

    Abstract Small molecule inhibitors of glutaminase (GSL1) are described as potential treatment of metabolic diseases including obesity, diabetes, liver diseases, muscular atrophy and atherosclerosis. Glutaminolysis is an alternative to glycosis as a source of carbon for energy homeostasis and is a major source of energy in the brain and other organs. Glutaminase (GSL1) is a mitochondrial enzyme converting glutamine into glutamate through glutaminolysis. Excessive glutaminolysis is associated with accelerated aging.

    2026
    引用
    AI阅读
    加入学术空间
    2Discovery of a Novel Chemical Scaffold for Dual MDM2 and MDM4 Inhibition
    Elizabeth A. Lopes,Ricardo J. F. Ferreira,Joana D. Amaral,Mi Wang,Saad Shaaban,Shaomeng Wang,Nuno Maulide,Cecília M. P. Rodrigues,Daniel J. V. A. dos Santos,Maria M. M. Santos

    Abstract p53 is frequently inactivated through overexpression of MDM2 and MDM4, highlighting the need for effective MDM2/MDM4 dual inhibitors. In this work, an MDM2/MDM4-based virtual screening led to the identification of etrasimod as dual MDM2/MDM4 inhibitor. Guided by structural insights, rational modification of the cyclopentyl substituent afforded a series of six cyclopenta[b]indole derivatives designed to improve interactions in the hydrophobic Leu-26 pocket in both proteins. This optimization resulted in enhanced dual inhibitory activity, with the most potent analogue bearing a 3,4-dichlorophenyl substituent exhibiting IC50 values of 1.6 μM (MDM2) and 2.6 μM (MDM4) in binding assays. Moreover, mechanistic studies in SJSA-1 cells demonstrated a significant increase in p53 steady-state protein levels, as well as cleaved caspase-3 and cleaved PARP, consistent with p53 pathway engagement and activation of apoptosis. Overall, this study identifies cyclopenta[b]indoles as a new chemical scaffold for dual MDM2/MDM4 inhibition providing a basis for further biochemical and cellular optimization.

    2026
    引用
    AI阅读
    加入学术空间
    3In This Issue, Volume 17, Issue 11
    Mélanie Uguen
    2026
    引用
    AI阅读
    加入学术空间
    4Discovery and in Vitro Characterization of Macrocyclic 2-(Heteroaryl)pyrimidine Inhibitors Targeting Wild-Type KRAS and G12D/G12V Mutants
    Casey J. N. Mathison, Wei Pei,Shanshan Yan, Ananda Herath, Cesar De Oliviera, Sarah E. Kochanek,Agnes Vidal-Biggart, Ritesh Tichkule, Jose Juarez,Yelena Sarkisova, David H. Jones,Michael DiDonato,

    KRAS mutations are key drivers of oncogenesis in numerous cancer types, with KRAS(G12V), KRAS(G12D), and KRAS(G12C) alterations being the most prevalent. While inhibitors targeting KRAS(G12C) have shown clinical success, challenges remain in addressing the broader spectrum of KRAS mutations. Our initial effort to discover a broad-based KRAS therapeutic was guided by a scaffold-hopping campaign inspired by compounds with demonstrated switch-II pocket engagement. While macrocyclization of a 2-(1-pyrazolyl)pyrimidine core prototype did not yield suitable in vitro activity at the outset, it provided valuable insights into subsequent efforts. Refinement of our approach led to compound 1, which demonstrated high KRAS(G12V) binding affinity and concomitant biochemical potency in KRAS(G12V/G12D) mutants. Further physicochemical improvements led to the design of 2-(3-isoxazolyl)pyrimidine macrocycles with improved permeability and in vitro mutant KRAS cellular activity.

    2026
    引用
    AI阅读
    加入学术空间
    5A High-Throughput Screening Platform for the Discovery of Noncovalent Inhibitors of the ISG15-UBA7 Interaction
    Trevor T. Dean, Tatum L. Johnson,Mohamed Haloul, Sweta Misra, Yuri Song,Kiira Ratia,Ekrem Emrah Er,Terry W. Moore

    Patients with metastatic breast cancer have a dismal five-year survival rate of 28% because these cancers develop resistance to multiple treatment modalities; thus, novel therapies are desperately needed. Interferon signaling gene signatures and the expression of interferon stimulated gene 15 (ISG15) have been linked to resistance to chemotherapy, radiotherapy, immunotherapy, and targeted therapy in patients, but there are no therapies that target ISG15 or the enzymatic machinery that enables its covalent conjugation to substrate proteins, such as its activating E1 enzyme UBA7. In this pilot study, we established an AlphaLISA-based high-throughput assay to identify inhibitors of the ISG15-UBA7 interaction. The assay demonstrated strong performance characteristics for high-throughput screening with a Z ' factor of 0.69, indicating excellent robustness and sensitivity. Screening a library of 880 compounds yielded three hits that inhibited the ISG15-UBA7 interaction. Two of these compounds were also found to reduce ISGylation in cell-based assays. Overall, these findings highlight the utility of AlphaLISA as a scalable platform for high-throughput screening of drug-like inhibitors targeting the ISGylation pathway.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 5198 篇论文

    高被引作者

    作者引用发文
    Claudiu Trandafir Supuran104748
    Ahmed F. Abdel-Magid985168
    Burgess Joelle L9335
    knight steven david9224
    Dashyant Dhanak8704
    Nathanael S. Gray85919
    Ke Ding82117
    Peter J. Tummino7992
    Glenn S. Van Aller7992
    Hua Yang7383

    高产作者

    作者引用发文
    Ram W Sabnis332315
    Robert Kargbo649228
    Ahmed F. Abdel-Magid985168
    Steven H Liang146100
    Gerard C Rosse13681
    Blass Benjamin15549
    Claudiu Trandafir Supuran104748
    Craig W. Lindsley71840
    Dennis Liotta40926
    Andrea Angeli45125

    相关期刊

    Bioorganic & Medicinal Chemistry
    Bioorganic & Medicinal Chemistry Letters
    Chemmedchem
    ACS chemical biology
    Expert opinion on therapeutic patents
    Future medicinal chemistry
    ACS pharmacology & translational science
    Expert Opinion on Drug Discovery
    Journal of Enzyme Inhibition and Medicinal Chemistry
    RSC Medicinal Chemistry